Option chain shows key data for CSL's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CSL.

CSL (OTC:CSLLY) Stock, Option Chain

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

QURE

Biotech

News

Health Care

Movers

Trading Ideas

General

CSLLY

CSL and uniQure&#39;s Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

uniQure/ CSL Behring&#39;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

GileadSciences.Shutterstock

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ABBV

GILD

Wall Street&#39;s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

10 Reasons Michigan's Bird Flu Strategy Is Stirring COVID-Era Anxiety In Farming Communities

Government

Large Cap

Financing

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5 cases.

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

CSL Ltd

Press Releases

CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

Small Cap

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

ARCT

ONTF

TVTX

Comments

CSL

CSL (CSLLY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell